How this company measures up on the fundamentals that matter
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading near fair value at $61 (estimated $65). Passes all ethical screens. Ranks better than 94% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-12 | HOCHMAN RODNEY F | Director | 1,618 | $100,365 | |
| 2026-05-08 | YANG WATKIN PHOEBE L | Director | 1,000 | $63,006 | |
| 2026-05-07 | YANG WATKIN PHOEBE L | Director | 3,586 | — | |
| 2026-05-07 | HOCHMAN RODNEY F | Director | 6,275 | — | |
| 2026-05-07 | MADDEN ANNE T | Director | 5,868 | — | |
| 2026-05-07 | CULP HENRY LAWRENCE JR. | Director | 7,743 | — | |
| 2026-05-07 | LESJAK CATHERINE ANNE | Director | 3,586 | — | |
| 2026-05-06 | CULP HENRY LAWRENCE JR. | Director | 80,805 | $5,000,076 | |
| 2026-05-06 | STROMBERG WILLIAM J | Director | 1,000 | $61,689 | |
| 2026-05-01 | SACCARO JAMES | Chief Financial Officer | 3,310 | $200,585 |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15